| Abstract: | Summary: IgA nephropathy (Berger's disease), the most common primary glomerulonephritis worldwide, leads to end-stage renal failure in 20–40% of patients after 20 years of clinical disease. No consensus has emerged about treatment to slow or prevent the loss of renal function, and in large part this has been due to a critical lack of understanding of the pathogenetic mechanisms. Several approaches that reduce glomerular scarring and inflammation in other renal diseases, including fish oil supplements, anti-inflammatory agents and angiotensin-converting enzyme inhibitors, have been used, with variable results. For patients reaching end-stage, transplantation has shown excellent long-term outcomes. |
